Novartis Sues Biogen, Others Over Gene Sequencing IP

Law360, New York (January 28, 2011, 6:43 PM EST) -- Novartis Vaccines and Diagnostics Inc. has accused three biopharmaceutical companies including AstraZeneca PLC subsidiary MedImmune LLC of manufacturing treatments that infringe its diagnostic gene sequence technology.

The Novartis AG subsidiary filed its complaint for patent infringement against MedImmune, Biogen Idec Inc. and Alexion Pharmaceuticals Inc. Wednesday in the U.S. District Court for the District of Delaware.

The defendants have directly infringed, contributorily infringed and induced infringement of U.S. Patent Number 5,688,688 by making or causing to be made drugs that help treat respiratory ailments, multiple sclerosis...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.